NCT00653419

Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions

Comparative, Randomized, Single-Dose, 2-Way Crossover Bioavailability Study of Par and Bristol-Myers Squibb (Buspar) 15 mg Buspirone HCl Tablets in Healthy Adult Males Under Fasting Conditions Following Administration of a 30 mg Dose

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 48 (actual)
• Sponsor: Par Pharmaceutical, Inc. · Industry
• Sex: Male
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

To compare the single-dose bioavailability of Par and Bristol-Myers Squibb Buspirone HCl Tablets

Detailed description

To compare the single-dose bioavailability of Par and Bristol-Myers Squibb (Buspar) 15 mg Buspirone HCl Tablets under fasting conditions, following administration of a 30 mg dose

Conditions

• To Determine Bioequivalence Under Fasting Conditions

Interventions

Type	Name	Description
DRUG	buspirone HCl	Tablets, 30 mg, single-dose
DRUG	Buspar	Tablets, 30 mg, single-dose

Timeline

• Start date: 1998-06-01
• Primary completion: 1998-09-01
• Completion: 1998-09-01
• First posted: 2008-04-04
• Last updated: 2008-04-04

Locations

1 site across 1 country: Canada